

# Study of tumour focused radiotherapy for bladder cancer

<b>Submission date</b> 14/10/2015	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 14/10/2015	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 27/11/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-different-ways-of-giving-radiotherapy-for-bladder-cancer-raider>

## Contact information

### Type(s)

Public

### Contact name

Ms Hannah Gribble

### Contact details

ICR-CTSU  
15 Cotswold Road  
Sutton  
United Kingdom  
SM2 5NG  
+44 (0)20 8722 4613  
RAIDER-icrctsu@icr.ac.uk

## Additional identifiers

### ClinicalTrials.gov (NCT)

NCT02447549

### Protocol serial number

18868

## Study information

**Scientific Title**

A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder (RAIDER)

**Acronym**

RAIDER

**Study objectives**

1. Stage I of the study aims to establish the feasibility of Dose escalated Adaptive tumour boost RT in a multi-centre setting
2. Stage II of the study aims to establish the toxicity of Dose escalated Adaptive tumour boost RT

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

London - Surrey Borders Research Ethics Committee, 22/05/2015, ref: 15/LO/0539

**Study design**

Randomized; Interventional; Design type: Treatment

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Bladder cancer

**Interventions**

Participants are randomly allocated to one of three three groups for a course of radiotherapy:

Group 1: Participants receive standard whole bladder radiotherapy (WBRT)

Group 2: Participants receive standard dose adaptive tumour focused radiotherapy (SART).

Three plans (small, medium & large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.

Group 3: Participants receive dose escalated adaptive tumour boost radiotherapy (DART). Three plans (small, medium & large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group.

Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.

Added 27/11/2025:

Additional Data Linkage Information:

Participants from this trial will also be included in the INTERACT project which will link to their data held by NHS England. For more information, please see the INTERACT website:

<https://www.icr.ac.uk/interact>.

**Intervention Type**

Procedure/Surgery

**Primary outcome(s)**

Feasibility and safety of the treatment is determined at the end of the treatment period

**Key secondary outcome(s)**

Ability to deliver SART and DART is determined at the end of the treatment period

**Completion date**

31/03/2029

## Eligibility

**Key inclusion criteria**

1. Written informed consent
2. Aged 16 years or over
3. Histologically or cytologically confirmed transitional cell carcinoma (TCC) of the bladder
4. Unifocal bladder TCC staged T2-T4a N0 M0
5. Fit to receive a radical course of radiotherapy
6. WHO performance status 0-2
7. Willing and able to comply with study procedures and follow up schedule

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

16 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

345

**Key exclusion criteria**

Current exclusion criteria as of 09/10/2018:

1. Nodal or metastatic disease
2. Multifocal invasive disease
3. Simultaneous TCC in upper tract or urethra
4. Pregnancy
5. Active malignancy within 2 years of randomisation (not including non melanomatous skin

carcinoma, previous non-muscle invasive bladder tumours, NCCN low risk prostate cancer (T1/T2a, Gleason 6 PSA <10), in situ carcinoma of any site)

6. Bilateral Hip replacements

7. Any other conditions that in the Principal Investigator's opinion would be a contra-indication to radiotherapy (e.g. previous pelvic radiotherapy/inflammatory bowel disease)

Previous exclusion criteria:

1. Nodal or metastatic disease

2. Widespread carcinoma in situ (CIS) or CIS remote from muscle invasive tumour or multifocal invasive disease

3. Simultaneous TCC in upper tract or urethra

4. Pregnancy

5. Active malignancy within 2 years of randomisation (not including non melanomatous skin carcinoma, previous non-muscle invasive bladder tumours, NCCN low risk prostate cancer (T1/T2a, Gleason 6 PSA <10), in situ carcinoma of any site)

6. Any other conditions that in the Principal Investigator's opinion would be a contra-indication to radiotherapy (e.g. previous pelvic radiotherapy/inflammatory bowel disease)

**Date of first enrolment**

23/09/2015

**Date of final enrolment**

31/03/2020

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**The Institute of Cancer Research**

15 Cotswold Road

Sutton

England

SM2 5NG

## **Sponsor information**

**Organisation**

The Institute of Cancer Research

**ROR**

<https://ror.org/043jzw605>

# Funder(s)

Funder type  
Charity

Funder Name  
Cancer Research UK

Alternative Name(s)  
CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type  
Private sector organisation

Funding Body Subtype  
Other non-profit organizations

Location  
United Kingdom

## Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary  
Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Participant information sheet	24/09/2024	11/10/2024	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Participant information sheet</a>		11/11/2025	11/11/2025	No	Yes
<a href="#">Plain English results</a>	Study website		13/12/2024	No	Yes
<a href="#">Study website</a>		11/11/2025	11/11/2025	No	Yes